Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Neil Singhania

Allergy & Immunology Arlington, TX Medical Doctor

NPI 1669535886 CMS profile 74986

5421 Matlock Rd, Arlington, TX 76018

Open in the dashboard

General payments

$25,520

839 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Neil Singhania of Arlington, TX is reported in the CMS Open Payments database as having received $25,520 across 839 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,180 124
2024 General $2,773 114
2023 General $2,820 149
2022 General $2,670 140
2021 General $2,078 120
2020 General $1,467 85
2019 General $7,531 107

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Neil Singhania
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Neil Singhania were reported at $6,180. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Neil Singhania Allergy & Immunology median Middle half National median
2019 $7,531 $594 $163–$1,512 $163
2020 $1,467 $426 $106–$1,233 $114
2021 $2,078 $638 $157–$1,708 $132
2022 $2,670 $790 $205–$1,961 $149
2023 $2,820 $852 $220–$2,147 $160
2024 $2,773 $865 $203–$2,267 $164
2025 $6,180 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. CSL Behring $4,875 73 payments
  2. GlaxoSmithKline, LLC. $4,529 127 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $3,412 23 payments
  4. AstraZeneca Pharmaceuticals LP $1,994 103 payments
  5. Regeneron Healthcare Solutions, Inc. $1,882 67 payments
  6. kaleo, Inc. $946 61 payments
  7. Novartis Pharmaceuticals Corporation $913 43 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $862 43 payments
  9. Genzyme Corporation $639 27 payments
  10. Covis Pharma B.V. $631 37 payments
  11. Other $4,836 235 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $16,589 825 payments
  2. Consulting Fee $5,795 3 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,855 3 payments
  4. Education $196 6 payments
  5. Travel and Lodging $85 2 payments
Products named General payments · program years 2019–2025
  1. Andembry $3,328 7 payments
  2. NUCALA $2,777 15 payments
  3. DUPIXENT Inflammation And Immunology $1,496 55 payments
  4. DUPIXENT Immunology $1,310 56 payments
  5. TRELEGY ELLIPTA $1,285 74 payments
  6. AUVI-Q $903 59 payments
  7. FASENRA $813 38 payments
  8. Haegarda $775 33 payments
  9. Hizentra $772 33 payments
  10. ALVESCO $631 37 payments
  11. Other $9,848 487 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

839 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record